358 related articles for article (PubMed ID: 16892382)
1. Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Vicker N; Lawrence HR; Allan GM; Bubert C; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
ChemMedChem; 2006 Apr; 1(4):464-81. PubMed ID: 16892382
[TBL] [Abstract][Full Text] [Related]
2. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
3. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
[TBL] [Abstract][Full Text] [Related]
4. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
[TBL] [Abstract][Full Text] [Related]
5. E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Fischer DS; Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Wood L; Packham G; Mahon MF; Reed MJ; Potter BV
J Med Chem; 2005 Sep; 48(18):5749-70. PubMed ID: 16134943
[TBL] [Abstract][Full Text] [Related]
6. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
Karkola S; Alho-Richmond S; Wahala K
Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
10. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
11. Novel, potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Reed MJ; Potter BV
Mol Cell Endocrinol; 2006 Mar; 248(1-2):204-7. PubMed ID: 16337736
[TBL] [Abstract][Full Text] [Related]
12. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
[TBL] [Abstract][Full Text] [Related]
13. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Mazumdar M; Fournier D; Zhu DW; Cadot C; Poirier D; Lin SX
Biochem J; 2009 Dec; 424(3):357-66. PubMed ID: 19929851
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
15. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Laplante Y; Rancourt C; Poirier D
Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
[TBL] [Abstract][Full Text] [Related]
16. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents.
Kruchten P; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):154-7. PubMed ID: 18984028
[TBL] [Abstract][Full Text] [Related]
17. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Lawrence HR; Vicker N; Allan GM; Smith A; Mahon MF; Tutill HJ; Purohit A; Reed MJ; Potter BV
J Med Chem; 2005 Apr; 48(8):2759-62. PubMed ID: 15828812
[TBL] [Abstract][Full Text] [Related]
18. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
[TBL] [Abstract][Full Text] [Related]
20. Improved synthesis of EM-1745, preparation of its C17-ketone analogue and comparison of their inhibitory potency on 17beta-hydroxysteroid dehydrogenase type 1.
Bérubé M; Poirier D
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):832-43. PubMed ID: 19003559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]